-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chilean researchers presented new results of Chile's COVID-19 vaccination program at the European Congress of Clinical Microbiology and Infectious Diseases (Lisbon, Portugal, 23-26 April)
The research results were also published in The Lancet Global Health on April 23, 2022
The study evaluated the efficacy of the CoronaVac (Kexing Bio), AZD1222 (Oxford/AstraZeneca) and BNT162b2 (Pfizer/BioNTech) vaccine boosters in individuals who had completed two doses of the Corona vaccine
The researchers evaluated individuals who were vaccinated between February 2, 2021, and November 10, 2021, while excluding individuals who had been infected with the new coronavirus or who had been vaccinated before that time
A total of 11.
The authors calculated that the two-dose vaccine plus the Kexing booster was 79% effective in preventing symptomatic COVID-19, the BNT162b2 booster was 97% effective, and the AZD1222 booster was 93% effective
The authors explain that booster programs have been launched in countries because of emerging evidence of weakened immunity with the two-dose regimen
They concluded: "Our results suggest that a third booster dose provides high levels of protection against COVID-19, including severe illness and death, in a population previously vaccinated with two doses of Sinovac vaccine.
The authors further explain that this is one of the first studies to examine the effectiveness of booster shots of an inactivated SARS-CoV-2 vaccine
A Cov-Boost study in a phase 2 clinical trial in the United Kingdom showed that after two doses of AZD1222 and BNT162b2 vaccinations, various vaccines were safe and immunogenic as boosters, and antibody levels after mRNA boosters were administered.
In Chile, the government now recommends that heterologous boosters be preferred; however, homologous boosters can be administered as an alternative
Original text retrieval
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study
